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Abstract
Background Low- and middle-income countries (LMICs)
face a number of challenges in implementing cervical
cancer prevention programmes that do not apply in high-
income countries.
Objective This review assessed how context-specific
challenges of implementing cervical cancer prevention
strategies in LMICs were accounted for in existing cost-
effectiveness analysis (CEA) models of human papillo-
mavirus (HPV) vaccination.
Methods The databases of MEDLINE, EMBASE, NHS
Economic Evaluation Database, EconLit, Web of Science,
and the Center for the Evaluation of Value and Risk in
Health (CEA) Registry were searched for studies published
from 2006 to 2015. A descriptive, narrative, and interpre-
tative synthesis of data was undertaken.
Results Of the 33 studies included in the review, the
majority acknowledged cost per vaccinated girl (CVG) (26
studies) and vaccine coverage rate (21 studies) as particular
challenges for LMICs, while nine studies identified
screening coverage rate as a challenge. Most of the studies
estimated CVG as a composite of different cost items.
However, the basis for the items within this composite cost
was unclear. The majority used an assumption rather than
an observed rate to represent screening and vaccination
coverage rates. CVG, vaccine coverage and screening
coverage were shown by some studies through sensitivity
analyses to reverse the conclusions regarding cost-effec-
tiveness, thereby significantly affecting policy
recommendations.
Conclusions While many studies recognized aspects of the
particular challenges of HPV vaccination in LMICs,
greater efforts need to be made in adapting models to
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account for these challenges. These include adapting
costings of HPV vaccine delivery from other countries,
learning from the outcomes of cervical cancer screening
programmes in the same geographical region, and taking
into account the country’s previous experience with other
vaccination programmes.
Key Points for Decision Makers
Cost per vaccinated girl, vaccine coverage and
screening coverage are highly uncertain parameters
in model-based cost-effectiveness analysis (CEA) of
human papillomavirus (HPV) vaccines in low- and
middle-income countries.
These uncertain parameters matter as they can
reverse the conclusions regarding cost-effectiveness
made by a CEA, thereby altering the resulting policy
choice.
More precise parameters could be obtained by
adapting costings of HPV vaccine delivery
conducted for other countries, observing the
outcomes of cervical cancer screening programmes
in the same geographical region, and taking into
account the country’s previous experience with other
vaccination programmes.
1 Introduction
The worldwide annual absolute incidence and mortality of
cervical cancer in 2012 was 528,000 and 266,000,
respectively, making it the fourth most common cancer
affecting women [1]. The global burden of mortality from
the disease falls disproportionately on low- and middle-
income countries (LMICs), which account for approxi-
mately 90 % of cervical cancer deaths [1]. Cervical cancer
and its precursor lesions can be detected by screening
women with screening technologies such as cytology-based
screening, visual inspection with acetic acid (VIA) and the
human papillomavirus (HPV) DNA test [2] and thus treated
at an earlier stage, thereby improving survival. The disease
can also be prevented by vaccination against oncogenic
HPV strains [2]. While screening and vaccination pro-
grammes have been effective in reducing cervical cancer
incidence in developed countries, LMICs have had diffi-
culties in implementing them [3, 4].
In 2009, the World Health Organization (WHO) rec-
ommended routine HPV vaccination for girls on the con-
dition that vaccination was found to be cost-effective when
assessed in the country or region in question [5]. A com-
prehensive cervical cancer prevention and control strategy
should include three levels of activity [2]: primary pre-
vention, involving HPV vaccination of girls (and boys if
affordable) between 9 and 13 years; secondary prevention,
in which women 30 years of age or older are ‘‘screened and
treated’’ with low-cost technologies especially for low-re-
source settings; and tertiary prevention, in which all
women with invasive cancer are to be treated as necessary.
Cost-effectiveness analysis (CEA) is a widely applied
method used to identify which health care interventions
deliver the best value for money. It identifies the most
effective health care intervention strategy while accounting
for the opportunity cost of other services foregone. A
comprehensive CEA of cervical cancer prevention involves
comparison of alternative prevention strategies, including
various screening intensities and/or vaccination. Numerous
studies assessing the cost-effectiveness of HPV vaccination
have been published for high-, middle- and low-income
countries. These typically employ decision analytic models
as many of the relevant outcomes will occur over periods
too long to practically assess within trials. CEAs of HPV
vaccination for LMICs often use and adapt decision ana-
lytic models employed by studies conducted in high-in-
come countries.
The challenges encountered by LMICs in implementing
cervical cancer prevention strategies are relevant for CEAs
of such programmes. Existing infrastructure may not have
the capacity to support adolescent vaccine delivery
requiring a substantial set-up cost [6, 7]. Adolescent vac-
cine delivery requires the following: (1) micro-planning to
assess issues of accessibility, geography, population
movements and cultural characteristics; (2) social mobi-
lization/information, education and communication to
increase vaccine awareness; (3) higher cold chain
requirements for delivery outside health facilities com-
pared with childhood immunization; and (4) greater service
delivery costs compared with childhood immunization [8].
Many LMICs lack the political commitment to maintain
vaccination infrastructure in the face of competing priori-
ties [9]. Additionally, weak surveillance capability prob-
lems also impact negatively on HPV immunization
coverage. Reaching girls who are not enrolled in schools is
also a considerable challenge [10]. Societal and cultural
issues related to poverty, illiteracy, religious taboos,
superstition, the influence of traditional/religious healers,
and an overemphasis on curative rather than preventive
medicine are all obstacles for effective vaccination [9]. For
instance, possibility of avoidance in vaccination partici-
pation by certain groups due to cultural and religious
sensitivities has been suggested, as the vaccines are offered
to prevent a sexually transmitted disease in young girls [6].
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As with vaccination, many LMICs lack resources to
establish systematic cervical cancer screening programmes
[10]. Routine screening is underutilized in LMICs because
of a lack of public health policy prioritization, professional
and general education, and media awareness, under-de-
veloped clinical facilities, inadequate financial resources
and, most crucially, insufficient capacity for effective fol-
low-up treatment of identified lesions [11]. As such, routine
screening is often unsustainable in many LMICs. Even
when achievable, screening programmes may only achieve
very low coverage. As an illustration, cervical cancer
screening coverage is less than 20 % in South Africa [12]
and about 8.7 % in Nigeria [13]. In Latin America, Costa
Rica, Bolivia, El Salvador, Nicaragua and Panama have
coverage rates ranging from 10 to 20 % [14].
These challenges in implementing and maintaining a
comprehensive cervical cancer prevention strategy make it
difficult to anticipate what programme coverage rates and
cost of vaccination might be realised. Both are crucial
parameters in most decision analytic models of HPV vac-
cination as they can determine whether vaccination is cost-
effective or not. Accordingly, such analyses need to
account for these distinct challenges, which do not apply to
high-income countries to the same extent, if the appropriate
policy advice is to be given.
Systematic reviews of CEAs of HPV vaccination in
LMICs have been published previously [15, 16]. Although
these previous works investigated how CEA results are
affected by model characteristics and underlying assump-
tions, they did not systematically consider how the context-
specific challenges posed by LMICs affect the results and
policy recommendations. Our review adds new insights by
assessing how context-specific challenges in implementing
and maintaining cervical cancer prevention and control
strategies in LMICs were accounted for in CEA models of
HPV vaccination. This review specifically examines the
following questions: (1) Does the existing HPV vaccination
cost-effectiveness literature acknowledge the particular
challenges of LMICs? (2) How were the LMIC-particular
challenges accommodated in the models? (3) Is the
uncertainty among the parameters that are particularly
sensitive to the implementation challenges in LMICs so
large that the policy recommendations are affected?
2 Methods
2.1 Eligibility Criteria
This systematic review was conducted in accordance with a
protocol registeredwith the International ProspectiveRegister
of Systematic Reviews (PROSPERO: CRD42015017870)
[7]. The review focused on studies on CEA of HPV
vaccination using decision analytic models [17]. Other
inclusion criteria were as follows: studies that considered the
cost-effectiveness of HPV vaccination and reported costs and
health effects in terms of quality-adjusted life years (QALYs),
disability-adjusted life years (DALYs) or life years gained
(LYGs); studies that were set in LMICs according to the
WorldBank classification [18]; selected articles includedboth
original research papers and reviews; studies published in any
language; and studies published since the first licensed vac-
cine in 2006.
2.2 Search Strategy and Data Extraction
MEDLINE (via PubMed), EMBASE, NHS Economic
Evaluation Database (NHS EED), EconLit, Web of Sci-
ence, and the Center for the Evaluation of Value and Risk
in Health (CEA) Registry were searched for eligible studies
on 15 March 2015. Cochrane Reviews, Cochrane DARE,
and Cochrane Health Technology Assessment Databases
were also searched for existing systematic reviews on the
cost-effectiveness of HPV vaccines. Reviews were inclu-
ded to ensure that no study was omitted.
Details of the search strategy used are presented in
Appendix 1 (Table 4). The reference lists of all relevant
articles identified during the search were reviewed to
identify further studies that were missed. Furthermore, the
PubMed ‘related articles’ were used to search for eligible
studies. Both screened titles or abstracts and retrieved
articles were managed using EndNote X7.3. Titles and
abstracts were screened for inclusion independently by OE
and TP using the eligibility criteria. The opinion of a third
reviewer (SL) was sought to arrive at a consensus in cases
where there was disagreement on a study for inclusion.
Data were extracted from included studies using a pre-
defined data extraction spreadsheet as per protocol [7].
2.3 Data Items
Characteristics of included studies were extracted (Ap-
pendix 2, Table 5). Context-specific challenges with vac-
cination and screening parameters were identified.
Furthermore, the accommodation of the context-specific
challenges in the decision analytic model and their influ-
ence on CEA estimates were examined and reported.
2.4 Quality Assessment
The included studies were assessed using the Consolidated
Health Economic Evaluation Reporting Standards
(CHEERS) statement [19]. CHEERS is a 23-item checklist
developed to aid transparency and clarity in the reporting
of economic evaluations. One point was allotted if a study
fulfilled each of the CHEERS statement items. Only those
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items applicable to the studies were considered. For
instance, item 12–measurement and valuation of preference
based outcomes–was omitted for some studies since it is
not applicable to all the studies.
3 Results
3.1 Search Results
Figure 1 shows a flow diagram of the study selection
process. The database searches yielded a total of 6151
abstracts/titles and 3585 abstracts/titles after removal of
duplicates. Another five studies were identified from
existing reviews. After screening of abstract and titles, 33
articles were retrieved for review [20–52] (Appendix 2).
The quality assessment score for each study is shown in the
final column of Table 5. The included studies conformed to
most of the CHEERS items (i.e. C19 points in a 22-point
scale), indicating acceptable overall reporting quality.
3.2 Context-Specific Uncertain Parameters
The majority of the studies (26) acknowledged cost per vac-
cinated girl (CVG) as a challenge. CVG was reported as
unknown, and thus analyses had to simulate an assumed CVG
[21–24, 26–29, 31, 33, 34, 37–46, 48–52]. Twenty-one studies
identified vaccine coverage as a challenge
[20, 24–26, 28–31, 33, 35, 36, 40–43, 46, 48–52], especially as
therewas no past experience ofHPVvaccination programmes
in the countries of study. Nine studies identified screening
coverage as a challenge [25, 26, 30, 31, 33, 34, 42, 43, 46, 49].
Of these nine studies, two applied the coverage of current
cervical cancer screening practice in a base case analysis and
assessed the impact of enhanced screening coverage on the
policy recommendation in the sensitivity analysis [31, 46].
The other seven studies assumed an organized national cer-
vical screening scenario [25, 26, 30, 34, 42, 43, 49]. Other
challenges acknowledged by studies were possible interrup-
tion of screening programme due to scarcity of funds [20];
patients lost to follow-up after screening or failure to treat
screen-detected disease [27, 30]; the prevalence and cost of
treating genital warts [35]; and uncertainty regarding sexual
mixing parameters [51].
3.3 Accommodation of Context-Specific Parameters
Most of the studies estimated CVG as an approximate
composite value that included vaccine cost, wastage, freight
and supplies, administration, immunization support and
programme costs [22, 25, 28–30, 32, 40–45, 48, 51, 52]. It
was not clear how the composite cost items were derived in
these studies. The composite costs were often varied over a
wide range of values in sensitivity analysis. Another study
used only the market prices of HPV vaccine in the base case
analysis and considered other vaccine delivery associated
























Additional records identified through 
hand search 
(n = 5)










based or conference abstract 
excluded, (n = 15)
Studies included in 
qualitative synthesis 
(n = 33)
Fig. 1 Flow diagram of study
selection process
68 O. I. Ekwunife et al.
costs (transportation, storage, product losses) in the sensi-
tivity analysis [20]. The primary rationale given for the
ranges of CVG or vaccine price used in the sensitivity
analysis was to determine a threshold price at which the
vaccine would be cost-effective.
All the studies where a vaccine coverage parameter
[26, 35, 42, 47] or a screening coverage parameter [42, 46]
was influential on the policy recommendation used an
assumption rather than an observed rate used in similar
context or pilot study. The assumed screening coverage
ranged from 20 to 100 %, with 70 % being the most
commonly used in the base case analysis. Similarly, the
assumed vaccine coverage rates ranged from 0 to 100 %,
with 70 % being the most commonly used in the base case
analysis. There was no rationale stated for the assumed
screening or vaccine coverage levels in these studies.
Details are shown in Table 1.
3.4 Influence of Context-Specific Parameters
on Policy Recommendation
Effect of sensitivity analysis on the policy recommendation
is shown in Table 2. From the base case analysis, 25 out of
the 33 studies recommended HPV vaccination (denoted by
a positive [?] sign), while four studies recommended
cervical cancer screening [20, 34, 46] or the current sce-
nario of no preventive intervention [38] (denoted by a
negative [-] sign). Eighteen studies found that uncertainty
surrounding CVG within the ranges they considered was
sufficiently large to change the policy recommendation
from acceptance to rejection or vice versa
[20, 22, 25, 27–30, 32, 34, 40, 41, 46–48, 50, 52]. Four
studies found uncertainty surrounding vaccine coverage
rate to be influential on the policy recommendation
[26, 35, 42, 47]. Two studies found uncertainty regarding
screening coverage rates to be influential on the policy
recommendation [42, 46]. Some studies conducted sensi-
tivity analyses for these context-specific parameters, but
did not report the results. Specifically, one study did not
report for CVG [37], seven studies did not report for
screening coverage rate [29, 30, 32, 41, 43, 45, 47], and six
studies did not report for vaccine coverage rate
[28–30, 32, 41, 43].
4 Discussion and Recommendations
This review identified parameters that were particularly
context-specific in CEAs of HPV vaccination and assessed
how they were accounted for in analyses in LMICs. This
review showed that the majority of the decision analytic
models of HPV vaccination did explicitly note that there
were LMIC-specific challenges. Although most of the
studies acknowledged specific challenges, the review also
showed that there is scope for improvement in how these
are managed. This section discusses the findings of the
review and makes recommendations for improved handling
of LMIC-specific challenges in CEAs of HPV vaccination.
The challenges most commonly identified were esti-
mates of CVG, vaccine coverage and screening coverage.
Other distinct challenges acknowledged by only a few
studies were interruption of screening programme, no
treatment following detection, loss of follow-up and sexual
mixing parameters. CVG was reported to significantly
affect policy recommendation by the majority of studies.
Vaccine coverage and screening coverage parameters were
reported to significantly affect the policy recommendation
by a few of the studies.
Previous literature has identified the scarcity, quality
and accessibility of data as a key challenge for those
conducting and using economic evaluations in many
LMICs in general [53]. Our analysis confirms this obser-
vation in the particular case of HPV vaccination. CVG,
screening coverage and vaccine coverage parameters are
inevitably uncertain as there typically was no prior expe-
rience of HPV vaccination, and cervical cancer screening
was mainly opportunistic in many of the contexts in which
the studies were conducted. Furthermore, there was con-
siderable uncertainty in the CVG because of a lack of
clarity on the vaccine’s cost prior to the pricing agreement
achieved by Gavi in 2013. In the specific case of the CVG,
the majority of the studies attempted to respond to such
data constraints by deriving a CVG estimate through a
composite costing approach. Nonetheless, they failed to
report and justify the basis for the composite cost items.
Vaccine coverage and screening coverage parameters were
simply assumed rather than being based on empirical evi-
dence of other vaccination programmes in the same setting
or HPV vaccination programmes in related settings. The
typical base case assumption of 70 % appears optimistic
given what has been achieved in other programmes
[22, 25, 30].
4.1 Cost per Vaccinated Girl
As has been stated previously, the lack of existing infras-
tructure to support vaccination of adolescent girls means
that delivery and programme costs could contribute sub-
stantially to total vaccination costs in LMICs [15]. Unlike
new infant vaccines, which may be added to an existing
infant vaccine delivery system, HPV vaccination requires
the development of a new vaccine delivery service in order
to achieve the required doses since the target age is dif-
ferent. Surprisingly, this need for an HPV-specific delivery
service was not accounted for by some of the studies.
Those that did consider the extra cost associated with HPV
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Table 1 Range used in sensitivity analysis and the rationale for use
No. First author, year Distinct
uncertain
parameters
Range used in sensitivity analysis Rationale
1 Aponte-Gonzalez
et al. 2013 [20]
CVG Bivalent vaccine: US$133–487
Quadrivalent vaccine: US$157–282
Range of vaccine cost was to determine threshold price
at which vaccine will be cost-effective
2 Berkhof et al. 2013
[21]
None – –





Vaccine coverage: base coverage of
70 % and attrition rate per dose of
15 % varied from 0 to 40 %
Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown. Vaccine coverage was assumed
4 Canfell et al. 2011
[23]
None – –
5 Colantonio et al.
2009 [24]
None – –
6 Diaz et al. 2008
[25]
CVG CVG: I$5–360 Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown





Vaccine coverage: 30–100 %
Range of CVG and vaccine coverage were authors’
judgment regarding uncertainty associated with
parameters
8 Ginsberg et al.
2009 [27]
CVG CVG: US$1.8–6 (i.e. US$0.6–2 per
dose)
Range of CVG was assumed





Vaccine coverage: 10–100 %
Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown. Range of vaccine coverage was assumed





Vaccine coverage: 0–90 %
Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown. Range of vaccine coverage was assumed
11 Goldie et al. 2008
[29]
CVG CVG: I$5–360 Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown
12 Goldie et al. 2008
[32]
CVG CVG: I$5–50 Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown







et al. 2008 [34]
CVG CVG: US$15.9–80 per dose Range of vaccine cost was to determine threshold price
at which vaccine will be cost-effective




Vaccine coverage: 20–85 % Range of vaccine coverage was assumed
17 Jit et al. 2014 [36] Not applicable – –
18 Kawai et al. 2012
[37]
None – –





Not applicable – –
21 Kim et al. 2007
[40]
CVG CVG: I$25–400 Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown
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vaccine delivery did not specify the basis for the cost
estimate and did not account for regional cost differences.
Regional cost differences matter for rural areas, which are
expected to have higher delivery costs than urban centres
as they may lack good road access and electricity supply to
maintain cold chain equipment.
Our proposal for refining CVG estimates for CEA of
HPV vaccination (i.e. cost of vaccine itself and all of the
costs of administration, distribution and implementation)
involves adaptation, to the country of study, of HPV vac-
cine delivery costs from other countries where vaccination
has been implemented. A number of pilot projects on HPV
vaccine delivery in LMICs have been conducted [54, 55].
These studies used various delivery methods, including
school-based periodic intensification of routine immu-
nization (PIRI), outreach vaccine delivery, PIRI integrated
with other preventive health activities, or routine provision
of health facility (fixed site)-based activities [8]. The cost
components of HPV vaccination from the pilot projects
typically include social mobilization, training, vaccine
procurement, vaccination, cold storage, waste management
and administration/supervision [54].
The adaptation process will firstly be to identify a pilot
HPV vaccine delivery project conducted in a similar
environment as the country of study. Then substitute as
many cost items of the HPV vaccine delivery project as
possible with country-specific costs. It may also be nec-
essary to combine different delivery methods in order to
target non-schooling populations. Fortunately, there is now
greater clarity on the vaccine cost for many countries, since
Gavi has secured a vaccine price of US$4.50 for eligible
nations (countries with less than US$1580 per capita
Table 1 continued
No. First author, year Distinct
uncertain
parameters
Range used in sensitivity analysis Rationale







Vaccine coverage: 20–100 %
Screening coverage: 20–100 %
Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown. Ranges of vaccine and screening coverage
rate were assumed
23 Kim et al. 2011
[44]
Not applicable – –
24 Kim et al. 2013
[41]
CVG CVG: I$5–360 Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown
25 Kim et al. 2013
[43]
CVG CVG: I$5–500 Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown









Screening coverage: 20–80 %
Range of CVG was to determine threshold price at
which vaccine will be cost-effective. Range of







Vaccine coverage: 0–100 %
Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown. Range of vaccine coverage rate was
assumed
29 Sharma et al. 2012
[48]
CVG CVG: I$10–500 Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown
30 Sinanovic et al.
2009 [49]
CVG CVG: US$192–480 per dose Range of CVG was to determine threshold price at
which vaccine will be cost-effective
31 Termrungruanglert
et al. 2012 [50]
CVG CVG: Bt6189–12,378 (US$177–354) Authors did not specify how CVG was estimated, nor
the reason for the range used in sensitivity analysis
32 Tracy et al. 2014
[51]
None – –
33 Vanni et al. 2012
[52]
CVG CVG: US$25–556 (US$5–120 per
dose)
Range of CVG was to determine threshold price at
which vaccine will be cost-effective since CVG was
unknown
Bt Baht, CC cervical cancer, CVG cost per vaccinated girl, HPV human papillomavirus, I$ international dollars, US$ US dollars
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income over the past 3 years) [56]. Repeating the analyses
using this price would now considerably reduce uncertainty
in the outcomes for the Gavi-eligible sub-Saharan African
countries reviewed here [22, 25, 32, 36, 38, 41, 44]. Non-
Gavi-eligible countries should use the lowest public sector
price of US$13 offered by HPV vaccine manufacturers
[56], as non-Gavi-eligible LMICs could likely negotiate
price down to this level, as achieved by the Pan American
Table 2 Effect of sensitivity analysis on policy recommendation (n = 33)







1 Aponte-Gonzalez et al. 2013 [20] - ? NA NA
2 Berkhof et al. 2013 [21] ?b NA ? NA
3 Campos et al. 2012 [22] ? - ? ?
4 Canfell et al. 2011 [23] NA NA NA NA
5 Colantonio et al. 2009 [24] ? NA ? NA
6 Diaz et al. 2008 [25] ? - NA NA
7 Fonseca et al. 2013 [26] ? NA NA -
8 Ginsberg et al. 2009 [27] ? - NA NA
9 Goldie et al. 2007 [30] ? - NR NR
10 Goldie et al. 2008 [28] ? - NA NR
11 Goldie et al. 2008 [29] ? - NR NR
12 Goldie et al. 2008 [32] ?b - NR NR
13 Goldie et al. 2012 [31] ? ? NA NA
14 Gutierrez-Aguado, 2011 [33] ? ? NA NA
15 Gutierrez-Delgado et al. 2008 [34] - ? NA NA
16 Insinga et al. 2007 [35] ? NA NA -
17 Jit et al. 2014 [36] NA NA NA NA
18 Kawai et al. 2012 [37] ? NR NA NA
19 Khatibi et al. 2014 [38] - - NA NA
20 Kiatpongsan and Kim, 2014 [39] NA NA NA NA
21 Kim et al. 2007 [40] ? - NA ?
22 Kim et al. 2008 [42] ? - - -
23 Kim et al. 2011 [44] NA NA NA NA
24 Kim et al. 2013 [41] ?b - NR NR
25 Kim et al. 2013 [43] ?b - NR NR
26 Levin et al. 2015 [45] ? ? NR ?
27 Praditsitthikorn et al. 2011 [46] - ?c ? -
28 Reynales-Shigematsu et al. 2009 [47] ? - NR -
29 Sharma et al. 2012 [48] ? - ? ?
30 Sinanovic et al. 2009 [49] ?c ?d NA NA
31 Termrungruanglert et al. 2012 [50] ? - NA ?
32 Tracy et al. 2014 [51] ? NA NA ?
33 Vanni et al. 2012 [52] ? - ? ?
Number of studies that parameter uncertainty affected policy recommendation 18 2 4
Number of studies that did not report the effect of parameter uncertainty 1 7 6
? Accept vaccination, - reject vaccination, CVG cost per vaccinated girl, NA not applicable, NR not reported
a Some studies were denoted NA since the primary focus was to explore price range for which vaccine would be cost-effective or to develop a
generic model for cost-effectiveness analysis
b Majority of the countries in multi-country study
c Accept vaccination in combination with screening
d Vaccine is more cost-effective than screening
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Health Organization countries [56]. It is important to note
that some of the more recent studies reviewed have already
adopted the approach we recommend for assessing the
CVG [36, 45].
4.2 Vaccine Coverage
The incremental cost-effectiveness ratio (ICER) of many
interventions in general may be invariant with the pro-
portion of the population treated, as costs and health effects
increase proportionately as coverage increases. It is
uncertain quite to what extent this can be expected to hold
in the case of HPV vaccination, due to herd immunity
effects, which mean the effectiveness of vaccination does
not necessarily rise in proportion with coverage. For
instance, one of the studies showed that at coverage levels
between 50 and 70 %, indirect effect of vaccination
accounted for an additional 10 % cancer reduction com-
pared with the mean projected estimate in the base case
[30]. Moreover, the ICER may not be invariant with cov-
erage if a vaccination programme’s fixed costs of organi-
zation and distribution are not small relative to the variable
costs of vaccine doses and administration. However, what
matters more is not that the ICER might vary with vaccine
coverage, but that it might vary to such an extent that the
policy recommendation might change. Indeed, our results
suggest the coverage rate appears to be a relevant param-
eter, as it altered the policy recommendation in just under
half of the studies reviewed (four out of nine) when varied
in sensitivity analyses.
The vaccination rate of 70 % commonly assumed by the
reviewed studies does not appear justified by the rates
achieved in practice by many LMICs. Even though school-
based HPV vaccination demonstration projects in some
LMIC settings have achieved high vaccine coverage of
between 80 and 95 % [57], the concern is that school-based
vaccination may miss a large number of girls not attending
schools. Similarly, some girls could also be systematically
excluded because they live in remote locations. Further-
more, as of 2010, most of the Middle East and North
African countries that adopted adolescent vaccine pro-
grammes to provide catch-up or booster vaccine adminis-
tered as recommended by the Eastern Mediterranean
Region of WHO (EMR) had low vaccine coverage, ranging
from 17 to 58 % [6]. Even many high-income country HPV
vaccination programmes have failed to achieve coverage
rates as high as 70 %. For example, low rates of complete
HPV vaccination coverage have been observed both in the
target and catch-up groups in France (33.3 and 23.7 %,
respectively) [58]. Only a few developed countries, such as
Australia, Canada, Portugal and the UK, have achieved
HPV vaccination coverage rates above 70 % [15]. This has
been attributed to the advantages of being able to rely on
existing adolescent health systems such as school nurses
[59].
Instead of assuming an unrepresentatively high coverage
rate, we believe that it will be most appropriate to use
previous country-specific vaccine coverage performance as
a base case assumption. Coverage rates of adolescent
catch-up or booster vaccination programmes could be used
in countries or regions where such programmes are in
place, such as in the Middle East and North African region
[6]. However, in the absence of an adolescent vaccination
programme, coverage of diphtheria-tetanus-pertussis
(DTP3) could serve as a good proxy, especially as vacci-
nation coverage with the third dose of DTP vaccines
among infants is the main indicator of immunization pro-
grammes’ performance and is used as a benchmark to
qualify for Gavi support [6].
4.3 Screening Coverage
Effective screening programmes require a number of
properties, including a well-organized call–recall system,
an accurate register of women and their screening history,
adequate follow-up and treatment for screen-positive
women, rigorous quality control to ensure good test accu-
racy and good screening coverage rates across the eligible
population. Accordingly, there are many screening vari-
ables for CEA modellers to consider when specifying their
analyses. In particular, modellers face a choice of whether
they should simulate screening as is as effective as possible
given available resources, or if they should simulate
screening as is currently practised.
We have primarily considered the choice of modelling
ideal or actual screening in terms of screening coverage.
This is because the assumed coverage rate is a key indi-
cator of whether the analysts are attempting to model the
best possible screening performance or what is more likely
to be attained in practice. Our results show that a clear
majority of the studies (seven of the nine reviewed) chose
to simulate organized national screening programmes with
relatively high coverage rates, while the remaining two
modelled screening coverage as currently achieved by the
health system.
There is no clear answer which approach is most
appropriate. Conventional CEA methods suggest that all
possible alternatives should be considered; therefore, well-
functioning national screening programmes with good
coverage appear relevant comparators to include. Whereas,
a more pragmatic view would be that many LMICs will
struggle to implement comprehensive national screening
programmes with high coverage rates. The relevant con-
cern regarding the assessment of vaccination is that
assuming unrepresentatively high screening rates will
result in under-estimates of the beneficial effects of
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vaccination, as primary prevention will lead to greater
added benefit when there is little secondary prevention.
Such assumptions therefore lead to unnecessarily unfa-
vourable cost-effectiveness estimates for vaccination.
These concerns are particularly relevant for those
LMICs that have no prior experience of implementing
national screening services. Accordingly, it is difficult to
make informed assumptions about what the potential for
organized screening is if there is no current programme.
Indeed, it may be questioned if such countries will be able
to implement a well-organized, high-quality screening
programme, in the medium term at least.
The experience of South Africa provides a useful illus-
tration of this issue. It is the only country within the
African region with an organized national cervical cancer
screening programme and has achieved cervical cancer
screening coverage of less than 20 % [12]. Some Latin
American countries such as Costa Rica, Bolivia, El Sal-
vador, Nicaragua, and Panama have screening coverage
rates ranging from 10 to 20 % [14]. With limited avail-
ability of cervical cancer screening tests and procedures at
the primary health care level (cervical cytology available in
57 % and acetic acid visualization in 29 % of the primary
health care centres in LMICs), it is doubtful whether
coverage levels of 70 % are achievable in LMICs [60].
Accordingly, we recommend the use of cervical cancer
screening coverage rates of countries in the same geo-
graphical region for analysis, assuming an organized
national screening or increased future predicted screening.
For instance, in the absence of local data, African countries
could employ the South African screening rates as the base
case rather than assuming 70 % coverage.
Although there is considerable uncertainty regarding
what coverage rates are feasible, it is notable that the policy
recommendations appear less sensitive to assumptions
regarding screening coverage than those regarding vacci-
nation coverage, as only two of the nine reviewed studies
saw their policy recommendations reverse when screening
adherence rates were varied in sensitivity analyses.
4.4 Sensitivity Analyses
A general response to the data limitations taken by many of
the reviewed studies was to examine the consequences of
parameter uncertainty in a sensitivity analysis. Although
this is an appropriate response to uncertainty, some further
issues arise from exactly how such analyses are conducted.
One particular difficulty occurred when broad ranges of
input parameters were specified for parameters such as the
CVG, vaccine coverage and screening coverage, which
resulted in a broad range of cost-effectiveness outcomes,
leaving it unclear as to whether the intervention was cost-
effective or not.
It is undeniable that considerable uncertainty does exist
in key parameters. Accordingly, large input parameter
ranges are necessary to a degree. However, the concern is
not necessarily just the size of the input parameter ranges,
but whether the analyses provided a justification for the
ranges used. The rationale for the input parameter ranges
used in the sensitivity analyses was typically not given in
the studies reviewed here. Accordingly, it is unclear if the
resulting uncertainty in cost-effectiveness estimates is
simply a fair reflection of the inherent decision uncer-
tainty resulting from appropriately quantified input
parameter ranges or if arbitrarily large input parameter
ranges are leading to unnecessary uncertainty for decision
makers. While there are theoretical arguments to suggest
that such decision uncertainty should not influence policy
[61], evidence suggests that uncertainty does matter to
decision makers [62]. Accordingly, the concern that
analysts may be overestimating the amount of uncertainty
and placing an unnecessary burden on LMIC decision
makers is relevant.
Our recommendation for the conduct of uncertainty
analysis is that the input parameter ranges chosen should be
chosen so they meaningfully reflect plausible ranges rather
than being arbitrarily chosen. While parameter uncertainty
is inevitable, if it is at all possible, more precise input
parameter distributions that yield less uncertain CEA out-
comes should be used. Similarly, we suggest that the
rationale for the input parameter ranges should be descri-
bed carefully. Table 3 contains specific recommendations
for the reduction of the decision uncertainty of important
input parameters in this case. These steps should ensure
greater clarity for decision makers for LMICs in their
policy choices.
4.5 Context of Implementation
The issue of screening and vaccine coverage examined
in this review can also be considered in the context of
the literature examining the implementation of inter-
ventions. Previous work has drawn attention to the issue
that guidelines, such as national screening and vaccina-
tion guidelines, are not always implemented as planned
[63]. Failure to adequately implement cost-effective
interventions imposes costs in terms of lost net health
benefit [64]. Similarly, achieving implementation in
accordance with guidelines will typically require addi-
tional resources, the costs of which may be overlooked
in applied CEAs.
The example of cervical cancer prevention considered in
this review is particularly relevant to the implementation
literature for two reasons. The first is that the challenges of
implementation are particularly relevant where the cost-
effectiveness of one intervention is contingent on the level
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of implementation of another, as is the case here with
vaccination and screening. Similarly, questions of effective
implementation can be expected to be more pressing in an
LMIC context, where much of the supporting health sys-
tems infrastructure required to achieve consistent service
provision to the whole population and good levels of
compliance is likely to be weaker than elsewhere.
Our review highlights the choice between modelling
cervical cancer prevention strategies according to the
national policy guidelines or on the basis of the levels of
screening and vaccine coverage that are likely to be
achieved in practice. If modellers choose to simulate on
the basis of the recommended coverage, then it is nec-
essary to both describe the efforts required to achieve
full implementation and to incorporate the additional
costs of enhancing implementation.
5 Conclusion
This review showed that the majority of the decision
analytic models of HPV vaccination did explicitly note
that there were LMIC-specific challenges. The chal-
lenges were mainly estimates of CVG, vaccine coverage
and screening coverage. CVG was reported to signifi-
cantly affect the policy recommendation in the majority
of the studies. Vaccine coverage and screening coverage
parameters were also reported to significantly affect the
policy recommendation in a few of the studies. CEAs of
HPV vaccination could achieve reduced decision
uncertainty by adapting cost analysis of HPV vaccine
delivery conducted for other countries, observing the
outcomes of cervical cancer screening programmes in
the same geographical region, and taking into account
the country’s previous experience with other vaccination
programmes.
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Appendix 1
See Table 4.
Table 3 Recommendation for improving the precision of policy recommendations of cost-effectiveness estimates of HPV vaccination in LMICs
Parameter Recommendation Example
Cost per vaccinated girl (CVG)
Vaccine price Use the HPV vaccine price offered by the
Vaccine Alliance (Gavi) for countries eligible
for Gavi support and lowest public sector
price offered by HPV vaccine manufacturers
for non-Gavi-eligible countries
US$4.50 per dose for Gavi-eligible
countries and US$13 per dose for non-
Gavi-eligible countries
Other cost (social mobilization, training,
vaccine procurement, vaccination, cold
storage, waste management and
administration/supervision)
Adapt the HPV vaccine delivery cost of other
countries, where it has been established, to
the country of study
Costing of HPV vaccine delivery to school
girls in Mwanza Region, Tanzania
adapted to other sub-Saharan African
countries [54]
Vaccination coverage rate Use previous country-specific vaccine coverage
performance
33 % coverage of second dose of diphtheria
toxoid, tetanus toxoid and pertussis (DTP)
vaccine in Nigeria [65]
Screening coverage rate Use cervical cancer screening coverage rate of
countries in the same geographical region
\20 % coverage rate of South Africa for
sub-Saharan African countries [12]
HPV human papillomavirus, LMICs low- and middle-income countries, US$ US dollars
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Appendix 2
See Table 5.




(‘‘Human papillomavirus 6’’ [mesh] OR ‘‘Human papillomavirus 16’’ [mesh] OR ‘‘Human papillomavirus 18’’ [mesh]
OR ‘‘Human papillomavirus 31’’ [mesh] OR Alphapapillomavirus [mesh] OR Papillomavirus* [tiab] OR human
papilloma* [tiab] OR HPV [tiab] OR ‘‘Papillomavirus Infections’’ [mesh] OR Papillomaviridae [mesh] OR
Papillomavirid* [tiab] OR Uterine Cervical Neoplasms [mesh] OR cervix cancer* [tiab] OR cervix carcinom* [tiab]
OR cervix malignan* [tiab] OR cervix neoplas* [tiab] OR cervix tumor* [tiab] OR cervical cancer* [tiab] OR cervical
carcinom* [tiab] OR cervical malignan* [tiab] OR cervical neoplas* [tiab] OR cervical tumor* [tiab] OR Cervical
Intraepithelial Neoplasia [mesh] OR Cervical Intraepithelial Neoplasia [tiab] OR CIN [tiab])
AND
(Vaccination [mesh] OR mass vaccination [mesh] OR Papillomavirus Vaccines [mesh] OR vaccin* [tiab] OR
immunization [mesh] OR Immunization Programs [mesh] OR immuni* [tiab] OR ‘‘human papillomavirus vaccine L1,
type 6,11,16,18’’ [Supplementary Concept] OR ‘‘human papillomavirus vaccine, L1 type 16, 18’’ [Supplementary




(Economics [mesh] OR Quality of Life [mesh:NoExp] OR Value of Life [mesh:NoExp] OR Quality-Adjusted Life Years
[mesh:NoExp] OR Models, Economic [mesh:NoExp] OR Markov Chains [mesh:NoExp] OR Monte Carlo Method
[mesh:NoExp] OR Decision trees [mesh:NoExp] OR economic* [tiab] OR cost* [tiab] OR costing* [tiab] OR costly
[tiab] OR costed [tiab] OR price* [tiab] OR pricing* [tiab] OR pharmacoeconomic* [tiab] OR pharmaco-economic*
[tiab] OR budget* [tiab] OR expenditure* [tiab] OR (value [tiab] AND (money [tiab] OR monetary [tiab])) OR fee
[tiab] OR fees [tiab] OR quality of life [tiab] OR qol* [tiab] OR hrqol* [tiab] OR quality adjusted life year* [tiab] OR
qaly* [tiab] OR cba [tiab] OR cea [tiab] OR cua [tiab] OR utilit* [tiab] OR markov* [tiab] OR monte carlo [tiab] OR
(decision [tiab] AND (tree* [tiab] OR analys* [tiab] OR model* [tiab])) OR ((clinical [tiab] OR critical [tiab] OR
patient [tiab]) AND (path* [tiab] OR pathway* [tiab])) OR (managed [tiab] AND (care [tiab] OR network* [tiab])))
EMBASE (‘Human papillomavirus type 6’/exp OR ‘Human papillomavirus type 16’/exp OR ‘Human papillomavirus type 18’/exp
OR ‘Human papillomavirus type 31’/exp OR ‘Alphapapillomavirus’/exp OR ‘Papillomavirus Infection’/exp OR
‘Papilloma virus’/exp OR ‘uterine cervix cancer’/exp OR (Papillomavirus* OR human papilloma* OR HPV OR
Papillomavirid*):ab,ti OR ((cervix OR cervical) NEAR/3 (cancer* OR carcinoma* OR malignanc* OR neoplasm* OR
tumor*)):ab,ti OR ‘uterine cervix carcinoma in situ’/exp OR (‘‘Cervical Intraepithelial Neoplasia’’ OR CIN):ab,ti)
AND
(‘Immunization’/exp OR ‘Cancer immunization’/exp OR ‘mass immunization’/exp OR ‘Vaccination’/exp OR ‘Wart




(‘health economics’/exp OR ‘health care cost’/exp OR ‘quality of life’/exp OR ‘quality adjusted life year’/exp OR
‘Monte Carlo method’/exp OR ‘decision tree’/exp OR (economic* OR cost* OR costing* OR costly OR costed OR
price* OR pricing* OR pharmacoeconomic* OR budget* OR expenditure* OR fee OR fees OR ‘quality of life’ OR
qol* OR hrqol* OR qaly* OR CBA OR CEA OR CUA OR utilit* OR markov*):ab,ti OR (pharmaco NEXT/1
economic*):ab,ti OR (value NEAR/1 (money OR monetary)):ab,ti OR (‘quality adjusted life’ NEXT/1 year*):ab,ti OR
(monte NEXT/1 carlo):ab,ti OR (decision NEXT/3 (tree* OR analys* OR model*)):ab,ti OR ((clinical OR critical OR
patient) NEXT/1 (path* OR pathway*)):ab,ti OR (managed NEXT/3 (care OR network*)):ab,ti)
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